AnaptysBio Announces Q2 FY2026 Results and Jemperli Updates
Jemperli global net sales rose 34% year-over-year to $644 million. The company reported positive interim results for the AZUR-1 pivotal trial and anticipates a 2027 FDA decision on expansion to rectal cancer.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed